Kathryn Gregory

Kathryn J.
Gregory was the founder of Seneb Biosciences, Inc., founded in 2009, where the title held was Chief Executive & Business Officer from 2009 to 2017.
Current jobs include Independent Director at Devonian Health Group, Inc. starting in 2024, and Vice President & Head-Business Development at Rgenta Therapeutics, Inc. Former jobs include Executive Director-Business Development at Purdue Pharma LP from 2015 to 2017; Associate Director-Business Development at Gensia Sicor Pharmaceuticals, Inc. from 1988 to 1998; Director-Business Development at Cytel Corp.
from 1998 to 1999; Vice President-Business Development & Licensing at Neose Technologies, Inc. from 1999 to 2010; Vice President-Business Development at PhaseBio Pharmaceuticals, Inc.; Chief Business Officer & Senior Vice President at Rein Therapeutics, Inc.; Head-Transactions at Shire Pharmaceuticals, Inc. from 2012 to 2015; Head-North America Sourcing & Procurement at Teva Pharmaceuticals Ltd.; Chief Business Officer at Avillion LLP from 2017 to 2018; President at Kg Biopharma Consulting LLC from 2018 to 2019; Independent Director at Longevity Health Holdings, Inc. from 2021 to 2026; Vice President & Head-Business Development at Antengene Corp.
Ltd. from 2021 to 2023; and Chief Business Officer at ReVision Therapeutics, Inc. Education includes an MBA from Pepperdine University and undergraduate studies at the University of California, Berkeley.